The France Scleroderma Therapeutics Market Size is Anticipated to reach USD 138.9 Million By 2035, Growing at a CAGR of 4.37% from 2025 To 2035. The France scleroderma therapeutics market is driven by increasing disease prevalence, advancements in immunosuppressive and antifibrotic therapies, and enhanced patient awareness. The France scleroderma therapeutics market focuses on treatments for scleroderma, a rare autoimmune disorder characterized by skin thickening and fibrosis of internal organs.